Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer - Test2 - elhamkhani - TriplyDB

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

http://www.wikidata.org/entity/Q26801357

about

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer Emerging therapeutic agents for lung cancer Second- and third-generation ALK inhibitors for non-small cell lung cancer Emerging roles of Nrf2 signal in non-small cell lung cancer Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer Recent advances of highly selective CDK4/6 inhibitors in breast cancer Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.Clinical applications of PD-L1 bioassays for cancer immunotherapy.Clinical decisions surrounding genomic and proteomic testing among United States veterans treated for lung cancer within the Veterans Health Administration.MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway.Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer.The expression profile and clinic significance of the SIX family in non-small cell lung cancer Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.A six-microRNA panel in plasma was identified as a potential biomarker for lung adenocarcinoma diagnosis.Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA.Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.Current status of research and treatment for non-small cell lung cancer in never-smoking females.MicroRNA-29a functions as a potential tumor suppressor through directly targeting CDC42 in non-small cell lung cancer Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers.The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer.The clinical significance of CXCL5 in non-small cell lung cancer.The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor.EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial.Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer.Effective assessment of low times MET amplification in pleural effusion after epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance: Cases report.Selective gene amplification to detect the T790M mutation in plasma from patients with advanced non-small cell lung cancer (NSCLC) who have developed epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance.Reliability of using circulating tumor cells for detecting epidermal growth factor receptor mutation status in advanced non-small-cell lung cancer patients: a meta-analysis and systematic review.

P2860

Q26741998-27BA8F30-C41D-4AC3-B3C3-E422E92661E9 Q26748851-3783E924-3EEC-40E2-8CEB-D022444BA67C Q28070165-D42540E7-813E-41B2-B3A1-80ED49DFA8D3 Q28072496-95863B0F-76E7-48E1-BA7E-7B85E8163585 Q28078928-92BD0B8F-D868-4AA6-A7F4-F7E8C8A7DD73 Q28079253-A69DB6C5-3612-4A75-9CFC-CD81C8F41825 Q33602076-19C965A6-D186-41BD-9A6B-F59D6884DABB Q33640472-BF3C4F3F-DCF1-4FB6-9B24-2F291327F974 Q33702815-62A4BF2C-3C12-4C50-9920-EFF7D9A2D379 Q33743535-55C578D3-9848-4856-9544-94CCE0B0F1CF Q33814564-E31C9768-D03F-4CB7-B20C-E2D8111975D6 Q33873095-48E6336C-2827-4EC5-9324-A8FE7F6E8CE6 Q36103228-B2F0D918-1502-46E2-B1B5-693A08665BD8 Q37051546-39D6416E-2B22-48E7-853C-93B9D4645D70 Q37233557-2A22867B-793D-4E74-92BF-90D90ED00473 Q37251422-CC9E177C-286D-4D95-819A-DCE122D0D149 Q37252696-4FEFECE3-3246-4DE1-990F-020DC570DBE8 Q37400801-EA050B79-3ADC-4FAC-A769-CB026B4D070F Q37536958-6C077F5D-F207-42AF-BF71-A901A07B52D1 Q37701630-1371A72F-AD52-4244-A99B-82EC8F44F843 Q37723666-5D0F58EF-07FD-47E4-AE3A-0730AA4F343D Q38988061-742016EB-0E0C-4ECC-B5AC-E656D58276F7 Q39298725-DA14E48A-9350-476C-8C4A-4AE49F86E998 Q42267770-25432B2C-C937-48DF-9FF1-FA321E23A8B8 Q42365337-3852EBFE-949F-4175-8B76-ABDB4872BFD3 Q42643276-F39386EB-04A0-44B6-9256-EDE22E179F92 Q47101861-22A737A0-51FB-4E6D-926E-1EFBED3D3583 Q47115593-F31C3782-8079-4E15-B107-9097C50BBCEE Q47836622-48E2E855-5723-4117-BABC-2C3FDA2C4C83 Q47883536-AA1CBB5D-745A-4956-A72A-759BED2F6066 Q50675249-E7A3ECF9-70FF-44FC-BBFB-CF382A248601 Q52674005-094B32C5-FA1F-4152-9E72-458C4A6B6ADE Q54113603-A4DE7BBC-7386-4C11-8382-F6A16752B256 Q54120286-2005C4D2-20C3-48AD-A74E-495515C1142B

P2860

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

http://www.wikidata.org/entity/Q26801357

description

2015 nî lūn-bûn

@nan

2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

@ast

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

@en

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

@nl

type

label

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

@ast

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

@en

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

@nl

prefLabel

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

@ast

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

@en

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

@nl

P1433

Q26801357-18594831-957D-4C0B-B61F-E8B6B3DBFF3C

P1476

Q26801357-CC865742-6FDE-454E-A104-06CCB62FB383

P2093

Q26801357-40A539AB-5358-4D6F-B439-546F855468B3

Q26801357-659833BC-543B-4597-981D-251C62FAF31D

Q26801357-892E1447-BEE1-465F-82D0-5397C32F851F

Q26801357-BCAED659-4179-42F7-86EF-E64437D098CA

Q26801357-C99B6C06-C224-4331-88DF-F7E77827997C

Q26801357-E240B4B6-92ED-40A0-A91D-B5627E7F3014

Q26801357-F3FA2B6C-55DC-46A3-B4A8-F2359132D546

P275

Q26801357-0D699917-080D-4B2C-B91E-44E0ECB6CD79

P2860

Q26801357-02DEF51E-CFBB-4383-9576-308EE02BB5CE

Q26801357-033BF61F-2AC4-4F59-9D0C-8104AAB3E0C4

Q26801357-0364CE2A-7493-45D7-903C-BB82DE10EC23

Q26801357-0B074F55-1749-4B33-963F-3B978486E02E

Q26801357-0E417B11-3324-4CD0-9074-71DD897FF253

Q26801357-0E6D7EC9-6DCF-4487-BBB0-64228D5F1F7A

Q26801357-17736171-6E56-41C7-A16E-72B9333F11F7

Q26801357-187C592B-37A9-4FD8-AE40-276809A4ADF6

Q26801357-1A86B4F5-348E-435D-80ED-498A0563D0A9

Q26801357-1B1F42E8-ECCD-4DF2-8465-C81C3CD2384D

P2888

Q26801357-EC20774D-9FBB-4B62-A035-B0CC4B11E42D

P304

Q26801357-E6150901-ED07-4F55-959F-DF4BA93D4386

P31

Q26801357-B681D7DC-FA8E-4084-AD33-3E2EE8F157DF

Q26801357-CA225E40-0AAE-43C8-8112-C502253575DB

P3181

Q26801357-C1A6C7ED-220C-4047-853D-E175ADE97793

P356

Q26801357-2C25962C-6003-4434-A514-34A6AE5801D1

P407

Q26801357-FE581003-7D6D-4059-B079-19089D2B1D28

P433

Q26801357-A321C778-5F4A-4E75-B9EC-771D425E7C0B

P478

Q26801357-8843EDAF-726A-43EA-B3AB-4F31D2462048

P5008

Q26801357-1FAE7CB4-635A-44EA-834B-E3C49715B2A1

P577

Q26801357-9DEA000A-5CFD-40CD-A6CC-4E6518D3E3F6

P5875

Q26801357-4EC6E2D3-E3A1-49BB-87A1-6C1496803136

P6179

Q26801357-9BA9CF35-7091-4E9B-929E-12D7D824215E

P698

Q26801357-67271173-8E58-44BB-BD14-028478FBA1E8

P921

Q26801357-4FDE4D05-AD72-4F08-8185-7BA3F4E289B7

Q26801357-74D14EC8-F5AD-49C2-9C3A-8D217937B789

Q26801357-8D343056-5026-4005-8CEA-FA25C20C521D

Q26801357-8E9B359A-8F70-4C6C-9B7C-60ACE49FE6B3

Q26801357-AD5C0CF3-96B4-4BD1-8490-091522A200E9

Q26801357-BEF06627-49E1-4AE8-BD66-F6DDD21E5405

Q26801357-C94D7A87-0B31-4A70-A50C-3E2517213672

Q26801357-F19619D9-7CF4-4D61-922E-6417F4CCDE1C

P932

Q26801357-3B174A70-B599-43CC-8DE3-32F69E6AF853

P3181

P356

S13045-015-0193-6

P1433

Journal of Hematology & Oncology

P1476

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

@en

P2093

Guoqing Hu

http://www.w3.org/2001/XMLSchema#string

Hanxiao Xu

http://www.w3.org/2001/XMLSchema#string

Hua Wu

http://www.w3.org/2001/XMLSchema#string

Kongming Wu

http://www.w3.org/2001/XMLSchema#string

Wei Sun

http://www.w3.org/2001/XMLSchema#string

Xun Yuan

http://www.w3.org/2001/XMLSchema#string

Yijun Tian

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

Global cancer statistics, 2012

Circulating microRNAs: potential biomarkers for common malignancies

Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer

Detection of mutations in EGFR in circulating lung-cancer cells

Epidermal growth factor receptor mutations in lung cancer

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

Strategies for modern biomarker and drug development in oncology.

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.

P2888

s13045-015-0193-6

P304

95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

8430

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/S13045-015-0193-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2015-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281817900

http://www.w3.org/2001/XMLSchema#string

P6179

1019544881

http://www.w3.org/2001/XMLSchema#string

P698

26227959

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

mechanism of action

non-small-cell lung carcinoma

membrane proteins

P932

4521383

http://www.w3.org/2001/XMLSchema#string